Information Provided By:
Fly News Breaks for August 27, 2019
CERS
Aug 27, 2019 | 16:20 EDT
Stifel analyst Mathew Blackman started Cerus with a Buy rating and $7 price target. The analyst sees "significant potential upside" over time as the company executes against "high-value" commercial and pipeline opportunities that he believes are not yet adequately reflected in the valuation. Cerus's blood pathogen-reduction technology has demonstrated commercial momentum over the past 12 months, and the company's billion-dollar-plus addressable market opportunities are only "marginally appreciated," Blackman tells investors in a research note.
News For CERS From the Last 2 Days
There are no results for your query CERS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.